In allergic rhinitis models, Rh1’s therapeutic efficacy operates through activation of the AMPK/ULK1/FUNDC1 pathway, which mediates mitochondrial autophagy and subsequently reduces NLRP3 inflammasome activation while restoring Th1/Th2 balance [128]. This evidence concerns the gene NLRP3 and allergic rhinitis.